689 related articles for article (PubMed ID: 32086346)
21. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Smith MR; Scher HI; Sandhu S; Efstathiou E; Lara PN; Yu EY; George DJ; Chi KN; Saad F; Ståhl O; Olmos D; Danila DC; Mason GE; Espina BM; Zhao X; Urtishak KA; Francis P; Lopez-Gitlitz A; Fizazi K;
Lancet Oncol; 2022 Mar; 23(3):362-373. PubMed ID: 35131040
[TBL] [Abstract][Full Text] [Related]
22. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
[TBL] [Abstract][Full Text] [Related]
23. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
[TBL] [Abstract][Full Text] [Related]
24. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
25. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Su CT; Nizialek E; Berchuck JE; Vlachostergios PJ; Ashkar R; Sokolova A; Barata PC; Aggarwal RR; McKay RR; Agarwal N; McClure HM; Nafissi N; Bryce AH; Sartor O; Sayegh N; Cheng HH; Adra N; Sternberg CN; Taplin ME; Cieslik M; Alva AS; Antonarakis ES
Prostate; 2023 Feb; 83(3):227-236. PubMed ID: 36382533
[TBL] [Abstract][Full Text] [Related]
26. Differential Activity of PARP Inhibitors in
Taza F; Holler AE; Fu W; Wang H; Adra N; Albany C; Ashkar R; Cheng HH; Sokolova AO; Agarwal N; Kessel A; Bryce A; Nafissi N; Barata P; Sartor AO; Bastos D; Smaletz O; Berchuck JE; Taplin ME; Aggarwal R; Sternberg CN; Vlachostergios PJ; Alva AS; Su C; Marshall CH; Antonarakis ES
JCO Precis Oncol; 2021; 5():. PubMed ID: 34778690
[TBL] [Abstract][Full Text] [Related]
27. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
[TBL] [Abstract][Full Text] [Related]
28. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
Shore N; Ionescu-Ittu R; Yang L; Laliberté F; Mahendran M; Lejeune D; Yu L; Burgents J; Duh MS; Ghate SR
Future Oncol; 2021 Aug; 17(22):2907-2921. PubMed ID: 33906368
[TBL] [Abstract][Full Text] [Related]
29. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Varnai R; Sipeky C
Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
[TBL] [Abstract][Full Text] [Related]
30. Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer.
Mouw KW; Choudhury AD
Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133
[TBL] [Abstract][Full Text] [Related]
31. Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
Saad F; de Bono J; Barthélémy P; Dorff T; Mehra N; Scagliotti G; Stirling A; Machiels JP; Renard V; Maruzzo M; Higano CS; Gurney H; Healy C; Bhattacharyya H; Arondekar B; Niyazov A; Fizazi K
Eur Urol; 2023 Apr; 83(4):352-360. PubMed ID: 35750582
[TBL] [Abstract][Full Text] [Related]
32. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
[TBL] [Abstract][Full Text] [Related]
33. PARP inhibitors in castration-resistant prostate cancer.
Tripathi A; Balakrishna P; Agarwal N
Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
[TBL] [Abstract][Full Text] [Related]
34. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
35. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
36. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
[TBL] [Abstract][Full Text] [Related]
37. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Anscher MS; Chang E; Gao X; Gong Y; Weinstock C; Bloomquist E; Adeniyi O; Charlab R; Zimmerman S; Serlemitsos-Day M; Ning YM; Mayrosh R; Fuller B; Trentacosti AM; Gallagher P; Bijwaard K; Philip R; Ghosh S; Fahnbulleh F; Diggs F; Arora S; Goldberg KB; Tang S; Amiri-Kordestani L; Pazdur R; Ibrahim A; Beaver JA
Oncologist; 2021 Feb; 26(2):139-146. PubMed ID: 33145877
[TBL] [Abstract][Full Text] [Related]
38. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
39. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme JJ; Taza F; De Sarkar N; Tewari AK; Arsalan Naqvi S; Riaz IB; Childs DS; Omar N; Adra N; Ashkar R; Cheng HH; Schweizer MT; Sokolova AO; Agarwal N; Barata P; Sartor O; Bastos D; Smaletz O; Berchuck JE; McClure H; Taplin ME; Aggarwal R; Sternberg CN; Vlachostergios PJ; Alva AS; Mehra N; Nelson PS; Hwang J; Dehm SM; Shi Q; Fleischmann Z; Sokol ES; Elliott A; Huang H; Bryce A; Marshall CH; Antonarakis ES
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38072760
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
Stopsack KH
Eur Urol; 2021 Apr; 79(4):442-445. PubMed ID: 33012578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]